Relapsing Forms of Multiple Sclerosis

Neurology
7
Pipeline Programs
1
Companies
7
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
1
3
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

U
DIROXIMEL FUMARATEApproved
diroximel fumarate
Unknown Company
oral2025
Biogen
VUMERITYApproved
diroximel fumarate
Biogen
oral2019

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Biogen
BiogenCAMBRIDGE, MA
7 programs
1
2
1
1
BG00012Phase 41 trial
Diroximel fumaratePhase 31 trial
BIIB091Phase 21 trial
dimethyl fumaratePhase 21 trial
Plasma exchangePhase 11 trial
+2 more programs
Active Trials
NCT01903291Completed333Est. Feb 2016
NCT02230969Completed1,208Est. Jan 2022
NCT00424788Completed12Est. Oct 2007
+4 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BiogenBG00012
BiogenDiroximel fumarate
BiogenBIIB091
Biogendimethyl fumarate
BiogenPlasma exchange
Biogenpeginterferon beta-1a
Biogendimethyl fumarate

Clinical Trials (7)

Total enrollment: 2,124 patients across 7 trials

NCT01873417BiogenBG00012

Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States

Start: May 2013Est. completion: Nov 2013237 patients
Phase 4Completed
NCT05083923BiogenDiroximel fumarate

A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)

Start: Nov 2021Est. completion: Sep 2024136 patients
Phase 3Completed
NCT05798520BiogenBIIB091

A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

Start: Jul 2023Est. completion: Feb 2026127 patients
Phase 2Completed
NCT02097849Biogendimethyl fumarate

Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.

Start: Feb 2015Est. completion: May 201671 patients
Phase 2Completed
NCT00424788BiogenPlasma exchange

A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)

Start: Jan 2007Est. completion: Oct 200712 patients
Phase 1Completed
NCT02230969Biogenpeginterferon beta-1a

Plegridy Observational Program

Start: Nov 2014Est. completion: Jan 20221,208 patients
N/ACompleted
NCT01903291Biogendimethyl fumarate

Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS

Start: Aug 2013Est. completion: Feb 2016333 patients
N/ACompleted

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
10h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
10h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
10h ago

Director of Finance

CoMind
London, UK
10h ago

Electronics Engineering Manager

CoMind
London, UK
10h ago

Director of Information Technology

Zavation Medical Products
10h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)